ReviewNature reviews. Gastroenterology & hepatology2011
New-generation vaccines against cholera.
Review in Nature reviews. Gastroenterology & hepatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Oral Cholera Vaccination Delivery Cost in Low- and Middle-Income Countries: An Analysis Based on Systematic Review.PLoS neglected tropical diseases · 2016Pooled it
- Post-licensure deployment of oral cholera vaccines: a systematic review.Bulletin of the World Health Organization · 2014Pooled it
- A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simultaneously with or without the buffering agent in healthy infants in India.Human vaccines & immunotherapeutics · 2018Trial
- Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.Clinical and vaccine immunology : CVI · 2016Trial
- Type 5 secretion system antigens as vaccines against Gram-negative bacterial infections.NPJ vaccines · 2024Review
- Article
- Mitogen-Activated Protein Kinases (MAPKs) and Enteric Bacterial Pathogens: A Complex Interplay.International journal of molecular sciences · 2023Review
- A scoping review of facilitators and barriers influencing the implementation of surveillance and oral cholera vaccine interventions for cholera control in lower- and middle-income countries.BMC public health · 2023Article
- Knowledge, Attitude, and Practice in a Sample of the Lebanese Population Regarding Cholera.International journal of environmental research and public health · 2022Article
- Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern.Frontiers in pharmacology · 2021Review
- An overview of VaxchoraHuman vaccines & immunotherapeutics · 2020Article
- A modified cholera toxin B subunit containing an ER retention motif enhances colon epithelial repairFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Feasibility and costs of a targeted cholera vaccination campaign in Ethiopia.Human vaccines & immunotherapeutics · 2018Article
- Oral administration of a recombinant cholera toxin B subunit promotes mucosal healing in the colon.Mucosal immunology · 2017Article
- Safety of a killed oral cholera vaccine (Shanchol) in pregnant women in Malawi: an observational cohort study.The Lancet. Infectious diseases · 2017Observational
- Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- The opportunities & challenges in delivering oral cholera vaccines.The Indian journal of medical research · 2016Article
- Vibrio cholerae Serogroup O139: Isolation from Cholera Patients and Asymptomatic Household Family Members in Bangladesh between 2013 and 2014.PLoS neglected tropical diseases · 2015Article
- Vaccines against enteric infections for the developing world.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015Review
- N-glycosylation of cholera toxin B subunit in Nicotiana benthamiana: impacts on host stress response, production yield and vaccine potential.Scientific reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholera is a major global health problem, causing approximately 100,000 deaths annually, about half of which occur in sub-Saharan Africa. Although early-generation parenteral cholera vaccines were abandoned as public health tools owing to their limited efficacy, newer-generation oral cholera vaccines have attractive safety and protection profiles. Both killed and live oral vaccines have been licensed, although only killed oral vaccines are currently manufactured and available. These killed oral vaccines not only provide direct protection to vaccinated individuals, but also confer herd immunity. The combination of direct vaccine protection and vaccine herd immunity effects makes these vaccines highly cost-effective and, therefore, attractive for use in developing countries. Administration of these oral vaccines does not require qualified medical personnel, which makes their use practical--even in developing countries. Although new-generation oral cholera vaccines should not be considered in isolation from other preventive approaches, especially improved water quality and sanitation, they represent important tools in the public health armamentarium to control both endemic and epidemic cholera.
Indexed as
Identifiers
22064524What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.